Connect Biopharma Holdings Limited (NASDAQ:CNTB) Short Interest Down 77.9% in March

Connect Biopharma Holdings Limited (NASDAQ:CNTB) was the target of a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 10,300 shares, a decline of 77.9% from the February 28th total of 46,700 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily trading volume, of 20,500 shares, the short-interest ratio is presently 0.5 days.

Institutional Trading of Connect Biopharma

Hedge funds and other institutional investors have recently bought and sold shares of the business. Choreo LLC purchased a new stake in shares of Connect Biopharma during the fourth quarter valued at $204,000. Catalina Capital Group LLC purchased a new stake in Connect Biopharma in the 4th quarter valued at about $66,000. Finally, Callan Capital LLC grew its stake in Connect Biopharma by 91.3% in the 4th quarter. Callan Capital LLC now owns 80,000 shares of the company’s stock worth $110,000 after acquiring an additional 38,177 shares in the last quarter. Hedge funds and other institutional investors own 58.72% of the company’s stock.

Connect Biopharma Trading Down 3.7 %

Shares of NASDAQ CNTB opened at $0.78 on Thursday. Connect Biopharma has a fifty-two week low of $0.77 and a fifty-two week high of $2.66. The business’s 50 day moving average price is $0.91 and its 200-day moving average price is $1.08.

Connect Biopharma Company Profile

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.